Pitfalls of FDA-Approved Germline Cancer Predisposition Tests
December 30, 2024
“The FDA approval on September 29, 2023, for 'class III de novo' blood tests to assess hereditary cancer risk make widely available tests that may be obtained through a Direct… read more